146 related articles for article (PubMed ID: 22533782)
1. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome.
Valassi E; Crespo I; Gich I; Rodríguez J; Webb SM
Clin Endocrinol (Oxf); 2012 Nov; 77(5):735-42. PubMed ID: 22533782
[TBL] [Abstract][Full Text] [Related]
2. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome.
Kamenický P; Droumaguet C; Salenave S; Blanchard A; Jublanc C; Gautier JF; Brailly-Tabard S; Leboulleux S; Schlumberger M; Baudin E; Chanson P; Young J
J Clin Endocrinol Metab; 2011 Sep; 96(9):2796-804. PubMed ID: 21752886
[TBL] [Abstract][Full Text] [Related]
3. A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome.
Valassi E; Aulinas A; Glad CA; Johannsson G; Ragnarsson O; Webb SM
Clin Endocrinol (Oxf); 2017 Nov; 87(5):433-439. PubMed ID: 28665508
[TBL] [Abstract][Full Text] [Related]
4. Ketoconazole therapy: an efficacious alternative to achieve eucortisolism in patients with Cushing's syndrome.
Moncet D; Morando DJ; Pitoia F; Katz SB; Rossi MA; Bruno OD
Medicina (B Aires); 2007; 67(1):26-31. PubMed ID: 17408017
[TBL] [Abstract][Full Text] [Related]
5. Effect of hypercortisolism control on high blood pressure in Cushing's syndrome.
Gómez RM; Albiger NM; Díaz AG; Moncet D; Pitoia FA; Bruno OD
Medicina (B Aires); 2007; 67(5):439-44. PubMed ID: 18051226
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the treatment of Cushing's syndrome using ketoconazole].
Conget JI; Halperin I; Vendrell J; Ferrer J; Martínez-Osaba MJ; Esmatjes E; Vilardell E
Med Clin (Barc); 1989 Nov; 93(14):531-4. PubMed ID: 2695699
[TBL] [Abstract][Full Text] [Related]
7. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole.
Corcuff JB; Young J; Masquefa-Giraud P; Chanson P; Baudin E; Tabarin A
Eur J Endocrinol; 2015 Apr; 172(4):473-81. PubMed ID: 25624013
[TBL] [Abstract][Full Text] [Related]
8. Ketoconazole- and Metyrapone-Induced Reductions on Urinary Steroid Metabolites Alter the Urinary Free Cortisol Immunoassay Reliability in Cushing Syndrome.
Vega-Beyhart A; Laguna-Moreno J; Díaz-Catalán D; Boswell L; Mora M; Halperin I; Casals G; Hanzu FA
Front Endocrinol (Lausanne); 2022; 13():833644. PubMed ID: 35282465
[TBL] [Abstract][Full Text] [Related]
9. Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole.
Feelders RA; Hofland LJ; de Herder WW
Neuroendocrinology; 2010; 92 Suppl 1():111-5. PubMed ID: 20829630
[TBL] [Abstract][Full Text] [Related]
10. Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN.
Valassi E; Franz H; Brue T; Feelders RA; Netea-Maier R; Tsagarakis S; Webb SM; Yaneva M; Reincke M; Droste M; Komerdus I; Maiter D; Kastelan D; Chanson P; Pfeifer M; Strasburger CJ; Tóth M; Chabre O; Krsek M; Fajardo C; Bolanowski M; Santos A; Trainer PJ; Wass JAH; Tabarin A;
Eur J Endocrinol; 2018 Apr; 178(4):399-409. PubMed ID: 29440375
[TBL] [Abstract][Full Text] [Related]
11. [Cushing's syndrome: clinical study of fifteen cases].
Calvo Romero JM; Morales Pérez F; Alvarez Barreiro JA; Diaz Pérez de Madrid J
An Med Interna; 1998 May; 15(5):237-40. PubMed ID: 9629768
[TBL] [Abstract][Full Text] [Related]
12. Metyrapone treatment in Cushing's syndrome: a real-life study.
Ceccato F; Zilio M; Barbot M; Albiger N; Antonelli G; Plebani M; Watutantrige-Fernando S; Sabbadin C; Boscaro M; Scaroni C
Endocrine; 2018 Dec; 62(3):701-711. PubMed ID: 30014438
[TBL] [Abstract][Full Text] [Related]
13. The medical management of Cushing's syndrome during pregnancy.
Lim WH; Torpy DJ; Jeffries WS
Eur J Obstet Gynecol Reprod Biol; 2013 May; 168(1):1-6. PubMed ID: 23305861
[TBL] [Abstract][Full Text] [Related]
14. Approach to the Patient Treated with Steroidogenesis Inhibitors.
Castinetti F; Nieman LK; Reincke M; Newell-Price J
J Clin Endocrinol Metab; 2021 Jun; 106(7):2114-2123. PubMed ID: 33675650
[TBL] [Abstract][Full Text] [Related]
15. Hepatic safety of ketoconazole in Cushing's syndrome: results of a Compassionate Use Programme in France.
Young J; Bertherat J; Vantyghem MC; Chabre O; Senoussi S; Chadarevian R; Castinetti F;
Eur J Endocrinol; 2018 May; 178(5):447-458. PubMed ID: 29472378
[TBL] [Abstract][Full Text] [Related]
16. Cushing's disease: adrenal steroidogenesis inhibitors.
Pivonello R; Simeoli C; Di Paola N; Colao A
Pituitary; 2022 Oct; 25(5):726-732. PubMed ID: 36036308
[TBL] [Abstract][Full Text] [Related]
17. Clinical features, diagnosis, treatment and molecular studies in paediatric Cushing's syndrome due to primary nodular adrenocortical hyperplasia.
Storr HL; Mitchell H; Swords FM; Main KM; Hindmarsh PC; Betts PR; Shaw NJ; Johnston DI; Clark AJ; Reznek RH; Grossman AB; Savage MO
Clin Endocrinol (Oxf); 2004 Nov; 61(5):553-9. PubMed ID: 15521956
[TBL] [Abstract][Full Text] [Related]
18. Updates in adrenal steroidogenesis inhibitors for Cushing's syndrome - A practical guide.
Varlamov EV; Han AJ; Fleseriu M
Best Pract Res Clin Endocrinol Metab; 2021 Jan; 35(1):101490. PubMed ID: 33707082
[TBL] [Abstract][Full Text] [Related]
19. [Medical treatment for Cushing's syndrome].
Nishikawa T; Saito J; Omura M
Nihon Rinsho; 2008 Jan; 66(1):186-91. PubMed ID: 18186263
[TBL] [Abstract][Full Text] [Related]
20. Management of diabetes mellitus in Cushing's syndrome.
Munir A; Newell-Price J
Neuroendocrinology; 2010; 92 Suppl 1():82-5. PubMed ID: 20829624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
